COMPREHENSIVE ANALYSIS OF CLINICAL NEUROPSYCHOLOGICAL AND NEUROIMAGING ASPECTS OF ALZHEIMER'S DISEASE
Ключевые слова:
Alzheimer's Disease, Clinical Symptoms, Neuropsychological Assessment, NeuroimagingАннотация
This comprehensive study conducted on 105 patients with Alzheimer's Disease (AD) at the Samarkand Regional Psychiatric Hospital provided pivotal insights into the clinical manifestations, risk factors, neuropsychological impacts, and neuroimaging aspects of AD. Participants, encompassing both genders and various forms of AD, were subjected to a detailed clinical assessment following the International Classification of Diseases 10th Revision (ICD-10). Clinically, the study uncovered a broad range of symptoms including headache, dizziness, nausea, sleep disturbances, anorexia, general weakness, and weight loss, reflecting the multifaceted impact of AD on patients' lives. Notably, the prevalence of symp-toms such as type II diabetes mellitus, chronic kidney disease, and chronic heart failure was higher in patients with the senile form of AD, emphasizing the need for personalized treatment approaches. Neuropsychological evaluation using the Mini Mental State Examination (MMSE) highlighted gender-based cognitive impairments, with male patients exhibiting more pronounced deficits. These findings underscore the importance of considering gender in AD research and treatment. Neuroimaging methods, particularly MRI and CT scans, played a crucial role in assessing brain atrophy. The study re-ported a decrease in the total volume of gray matter in AD patients, with atrophic changes observed in various brain re-gions. These neuroimaging findings are instrumental in enhancing diagnostic accuracy and tailoring treatment strategies. In conclusion, the study offers a holistic view of AD, contributing significantly to the understanding of its clinical, neu-ropsychological, and neuroimaging dimensions. The findings underscore the complexity of AD and highlight the neces-sity for ongoing research and innovation in its treatment and management.
Библиографические ссылки
Albert, M. S. (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 270-279,. https://doi.org/10.1016/j.jalz.2011.03.008.
Armstrong, R. A. (2019). Risk factors for Alzheimer’s disease. Folia neuropathologica, 57(2), 87-105,.
Bäckman, L., Jones, S., Berger, A.-K., Laukka, E. J., & Small, B. J. (2005). Cognitive impairment in preclinical Alzheimer’s disease: A meta-analysis. Neuropsychology, 19(4), 520,.
Dubois, B. (2014). Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria. The Lancet Neurology, 13(6), 614-629,.
Harper, L., Barkhof, F., Fox, N. C., & Schott, J. M. (2015). Using visual rating to diagnose dementia: A critical evaluation of MRI atrophy scales. Journal of Neurology, Neurosurgery & Psychiatry, 86(11), 1225-1233,.
Imabayashi, E. (2013). Comparison between brain CT and MRI for voxel‐based morphometry of A lzheimer’s disease. Brain and Behavior, 3(4), 487-493,. https://doi.org/10.1002/brb3.146.
Imtiaz, B., Tolppanen, A.-M., Kivipelto, M., & Soininen, H. (2014). Future directions in Alzheimer’s disease from risk factors to prevention. Biochemical Pharmacology, 88(4), 661-670,.
Jack, C. R., Jr. (2011). Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 257-262,.
Joe, E., & Ringman, J. M. (2019). Cognitive symptoms of Alzheimer’s disease: Clinical management and prevention. Bmj, 367, 2023.
Kelley, B. J., & Petersen, R. C. (2007). Alzheimer’s disease and mild cognitive impairment. Neurologic clinics, 25(3), 577-609,.
Koedam, E. L. G. E. (2011). Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol, 21(12), 2618-2625,. https://doi.org/10.1007/s00330-011-2205-4.
Kumar, K., Kumar, A., Keegan, R. M., & Deshmukh, R. (2018). Recent advances in the neurobiology and neuropharmacology of Alzheimer’s disease. Biomedicine & Pharmacotherapy, 98, 297-307,.
Larson, E. B., Kukull, W. A., & Katzman, R. L. (1992). Cognitive Impairment: Dementia and Alzheimer’s Disease. Annu. Rev. Public Health, 13(1), 431-449,. https://doi.org/10.1146/annurev.pu.13.050192.002243.
Lee, B. C. P., Mintun, M., Buckner, R. L., & Morris, J. C. (2003). Imaging of Alzheimer’s Disease. Journal of Neuroimaging, 13(3), 199-214,. https://doi.org/10.1111/j.1552-6569.2003.tb00179.x.
Lyketsos, C. G. (2011). Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimer’s & Dementia, 7(5), 532-539,.
McGeer, P. L. (1986). Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer’s disease. Neurology, 36(12), 1569-1569,.
Merriam, A. E., Aronson, M. K., Gaston, P., Wey, S., & Katz, I. (1988). The Psychiatric Symptoms of Alzheimer’s Disease. J American Geriatrics Society, 36(1), 7-22,. https://doi.org/10.1111/j.1532-5415.1988.tb03427.x.
Roehr, B. (2013). American psychiatric association explains DSM-5. Bmj, 346. https://www.bmj.com/content/346/bmj.f3591
Scheltens, P. (2016). Alzheimer’s disease. The Lancet, 388(10043), 505-517,.
Scheltens, P. (2021). Alzheimer’s disease. The Lancet, 397(10284), 1577-1590,.
Silva, M. V. F., Loures, C. D. M. G., Alves, L. C. V., Souza, L. C., Borges, K. B. G., & Carvalho, M. D. G. (2019). Alzheimer’s disease: Risk factors and potentially protective measures. J Biomed Sci, 26(1), 33,. https://doi.org/10.1186/s12929-019-0524-y.
Solfrizzi, V. (2011). Diet and Alzheimer’s disease risk factors or prevention: The current evidence. Expert Review of Neurotherapeutics, 11(5), 677-708,. https://doi.org/10.1586/ern.11.56.
Wenk, G. L. (2003). Neuropathologic changes in Alzheimer’s disease. Journal of Clinical Psychiatry, 64, 7-10,.
